Prognosis of acute coronary syndrome complicated by stress hyperglycemia after percutaneous coronary intervention therapy

被引:1
|
作者
申健 [1 ]
李志明 [1 ]
何丽珍 [1 ]
刘锦光 [1 ]
申源生 [1 ]
罗晓丽 [1 ]
机构
[1] Department of Cardiology,Huizhou Municipal Central Hospital
关键词
stress hyperglycemia; acute coronary syndrome; prognosis;
D O I
暂无
中图分类号
R541.4 [冠状动脉(粥样)硬化性心脏病(冠心病)];
学科分类号
1002 ; 100201 ;
摘要
Background Several studies have reported an association of hyperglycemia with increased mortality and complications in hospital patients with acute coronary syndrome(ACS).However,the influence of stress hyperglycemia(SH)on the medium-and long-term prognoses in ACS patients has not yet been determined.Methods Random venous blood glucose levels were determined in 433 ACS patients and the patients were divided into two groups based on blood glucose results and disease histories.The 171 patients included in the experimental group had no history of diabetes,had no diabetes and/or glucose metabolism disorders during hospitalization and follow-up and had fasting blood glucose levels of≥7.0 mmol/L and random blood glucose levels≥11.1 mmol/L.The 262 patients included in the control group had no history of diabetes,had no diabetes and/or glucose metabolism disorders during hospitalization and follow-up,and had fasting blood glucose levels<6.1 mmol/L and random blood glucose levels<7.8 mmol/L.Basic clinical information,coronary angiographic lesion characteristics,PCI success rate,complication rate,incidence and morbidity rate of cardiovascular events during the hospitalization period and 6 years of follow-up were compared between the two groups.Results There was no significant difference in age,gender or disease history between the two groups.The triglyceride levels and the left ventricular ejection fractions were significantly higher(P=0.00)and significantly lower(P=0.03)in the experimental group than in the control group,respectively.Both groups were subjected to coronary angiography and PCI.The PCI success rates of the two groups did not differ significantly(P=0.63).The experimental group had more type B2 lesions,but fewer type A lesions compared with the control group.The experimental group had significantly more stents implanted compared with the control group(P<0.05).The cardiovascular events were significantly increased(P=0.01)in the experimental group compared with the control group 1 year after discharge.The incidence of cardiovascular events did not differ significantly between the two groups 1-2 years after discharge.The event incidences were significantly higher(P=0.05)in the experimental group than in the control group at the end of follow-up.The experimental group was more prone to myocardial infarction and ischemic target vessel revascularization than the control group,but the control group was more prone to unstable stenocardia and heart failure than the experimental group.The psychogenic mortality of the two groups were similar.The interval and the overall mortality rates(P=0.054)of the two groups were also similar.Conclusions Patients with ACS complicated by SH were more likely to have cardiovascular events 1 year after PCI,whereas SH did not affect the mid-or long-term prognoses of these patients.SH is an independent risk factor for cardiovascular events.
引用
收藏
页码:243 / 251 +256
页数:10
相关论文
共 50 条
  • [31] Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: Balancing efficacy and bleeding risk
    Spinler, Sarah A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (15) : S7 - S17
  • [32] Antithrombotic therapy after acute coronary syndrome and/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot
    Lopes, Renato D.
    Hong, Hwanhee
    Alexander, John H.
    EUROPEAN HEART JOURNAL, 2019, 40 (46) : 3768 - 3770
  • [33] Antithrombotic Therapy for Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention
    Tseng, Andrew S.
    Shamoun, Fadi E.
    Marks, Lisa A.
    Agrwal, Neera
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2020, 120 (05): : 345 - 349
  • [34] Antiplatelet Therapy for Elderly Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
    Fioretti, Vincenzo
    Sperandeo, Luca
    Gerardi, Donato
    Di Fazio, Aldo
    Stabile, Eugenio
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (14)
  • [35] Effect of Previous Statin Therapy in Patients With Acute Coronary Syndrome and Percutaneous Coronary Intervention
    Yun, Kyeong Ho
    Shin, Ik-Sang
    Shin, Seoung-Nam
    Choi, Jun-Ho
    Kim, Seung Hwan
    Rhee, Sang Jae
    Lee, Eun Mi
    Yoo, Nam Jin
    Kim, Nam-Ho
    Oh, Seok Kyu
    Jeong, Jin-Won
    KOREAN CIRCULATION JOURNAL, 2011, 41 (08) : 458 - 463
  • [36] Feasibility and safety of non-contrast percutaneous coronary intervention in patients with complicated acute coronary syndrome
    Higuchi, S.
    Kabeya, Y.
    Nishina, Y.
    Miura, Y.
    Yoshino, H.
    EUROPEAN HEART JOURNAL, 2020, 41 : 1751 - 1751
  • [37] Sex disparities for clinical outcomes after percutaneous coronary intervention for acute coronary syndrome
    Sterpetti, Antonio V.
    Gabriele, Raimondo
    Di Marzo, Luca
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2024, 404
  • [38] Double Bifurcation Percutaneous Coronary Intervention in Acute Coronary Syndrome
    Alavi, Hosein
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (14) : S88 - S90
  • [39] Pharmacoeconomics of anticoagulants in acute coronary syndrome and percutaneous coronary intervention
    Huston, S. A.
    Hawkins, D.
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (12) : 1197 - 1204
  • [40] Bivalirudin in acute coronary syndrome's and percutaneous coronary intervention
    Lee, Michael S.
    Makkar, Rajendra R.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2006, 7 : S27 - S34